Polymer-Lipid Microparticles for Pulmonary Delivery

Toward engineering approaches that are designed to optimize the particle size, morphology, and mucoadhesion behavior of the particulate component of inhaler formulations, this paper presents the preparation, physicochemical characterization, and preliminary in vitro evaluation of multicomponent poly...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Langmuir : the ACS journal of surfaces and colloids. - 1992. - 34(2018), 11 vom: 20. März, Seite 3438-3448
1. Verfasser: Eleftheriadis, Georgios K (VerfasserIn)
Weitere Verfasser: Akrivou, Melpomeni, Bouropoulos, Nikolaos, Tsibouklis, John, Vizirianakis, Ioannis S, Fatouros, Dimitrios G
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Langmuir : the ACS journal of surfaces and colloids
Schlagworte:Journal Article Drug Carriers Excipients Pulmonary Surfactants 1,2-Dipalmitoylphosphatidylcholine 2644-64-6 Budesonide 51333-22-3 Polyvinyl Alcohol 9002-89-5 mehr... Chitosan 9012-76-4 Leucine GMW67QNF9C Lactose J2B2A4N98G
Beschreibung
Zusammenfassung:Toward engineering approaches that are designed to optimize the particle size, morphology, and mucoadhesion behavior of the particulate component of inhaler formulations, this paper presents the preparation, physicochemical characterization, and preliminary in vitro evaluation of multicomponent polymer-lipid systems that are based on "spray-drying engineered" α-lactose monohydrate microparticles. The formulations combine an active (budesonide) with a lung surfactant (dipalmitoylphosphatidylcholine) and with materials that are known for their desirable effects on morphology (polyvinyl alcohol), aerosolization (l-leucine), and mucoadhesion (chitosan). The effect of the composition of formulations on the morphology, distribution, and in vitro mucoadhesion profiles is presented along with "Calu-3 cell monolayers" data that indicate good cytocompatibility and also with simulated-lung-fluid data that are consistent with the therapeutically useful release of budesonide
Beschreibung:Date Completed 11.10.2018
Date Revised 11.10.2018
published: Print-Electronic
Citation Status MEDLINE
ISSN:1520-5827
DOI:10.1021/acs.langmuir.7b03645